DRTS Alpha Tau Medical - reports 100% objective response rate and 18.2-month median overall survival with Alpha dart plus pembrolizumab - No

DRTS Alpha Tau Medical - reports 100% objective response rate and 18.2-month median overall survival with Alpha dart plus pembrolizumab - No serious Alpha dart-associated adverse events; only two grade 1 events reported - Median overall survival 18.2 months, median progression-free survival 5.4 months with Alpha dart plus pembrolizumab